Our Cancer Genetic Testing
Turnkey Diagnostics cancer genetic testing (CGx) targets the most important genes associated with breast, colon, pancreatic, gynecological and melanoma cancers. These tests are ordered frequently by oncologists, as well as family doctors and internal medicine doctors that are primary care physicians and with patients with at-risk family histories.
Targets most important genes associated with cancers
Predicts the likelihood that a person will develop a disease
What is Genetic Testing for Cancer Risk?
Genetic testing for cancer risk is predictive testing, which means a test that can help predict the likelihood that an individual will develop cancer in his or her lifetime. Not everyone with a cancer‐related gene will develop cancer.
- Genetic testing helps predict the likelihood that a person will develop a disease, including some types of cancer.
- Genetic testing is a personal decision with many factors to consider.
- Anyone who decides to undergo genetictesting should receive genetic counseling before and after the test is performed.
Identify early & save lives
Who and Why to Test
The American Cancer Society has outlined certain factors associated with cancers that run in families. Physicians should consider CGx testing for any patient who has one or more of these family histories.
- Multiple cases of the same type of cancer, particularly if it is a rare or uncommon type of cancer
- Cancers occurring at younger-than-usual ages, such as colorectal cancer in a 22-year-old
- More than one type of cancer occurring in one family member, such as a female with both breast and ovarian cancer
- Cancers occurring in both of a pair of organs, such as both breasts, both kidneys, both eyes, both ovaries
- Cancer occurring in a gender not usually affected, such as breast cancer in a male relative
- Patients may initiate healthy lifestyle changes
- Cancer occurring across generations, such as grandmother, mother and daughter, or grandfather, father and son
- Childhood cancer occurring in more than one sibling, such as sarcoma in both a sister and brother
- Patients may begin to get cancer screens earlier and more often
- Patients may begin to monitor themselves closely for signs or symptoms of a particular type of cancer
- Patients may look in to preventive medications or surgery if recommended by a healthcare provider
My patients would benefit from testing
Statiscally Speaking
1 in 300 people may be carriers of a gene alteration associated with Lynch Syndrome Cancers associated with Lynch Syndrome are typically diagnosed at a young age
In 2020, an estimated 1,806,590 new cases of cancer were diagnosed in the United States and 606,520 people died from the disease.
Approximately 39.5% of men and women will be diagnosed with cancer at some point during their lifetimes (based on 2015–2017 data).
In 2020, an estimated 16,850 children and adolescents ages 0 to 19 will be diagnosed with cancer and 1,730 will die of the disease.
Cancer is among the leading causes of death worldwide. In 2018, there were 18.1 million new cases and 9.5 million cancer-related deaths worldwide.
By 2040, the number of new cancer cases per year is expected to rise to 29.5 million and the number of cancer-related deaths to 16.4 million.
Start with a free consultation
More Cancer Genetic Testing Info
Inherited Gene Mutations
Breast and Ovarian Cancer
ASCO Recommendations
While many inherited genetic variants are beneficial or neutral, others are harmful and believed to contribute to 5-10% of all cancers. Historical family patterns of certain types of cancer, along with other factors such as the age at which that cancer has typically developed, can signal inherited variant susceptibility syndrome.
Turnkey Diagnostics offers a multi-gene blood draw test that accurately identifies the presence of an inherited gene mutation or alteration. A patient who receives a negative test result will benefit from peace of mind knowing they did not inherit a harmful gene variant, while a patient who receives a positive test result will benefit from opportunities to better understand and potentially manage their cancer risk, and to make important decisions about their medical care.
In addition to determining an increased risk for developing cancer, our blood panel test also points to types of cancer screenings that should be conducted.
Inherited mutations in the genes of MLH1, MSH2, MSH6, PMS2 and EPCAM give a patient an increased lifetime risk of certain cancers. This genetic syndrome, known as Lynch syndrome and also called hereditary non-polyposis colorectal cancer (HNPCC), puts patients at a higher risk of certain types of cancer.
As a result of medical studies conduced recently, other cancers have been added, including prostate cancer, Muir Torre skin cancer and breast cancer.
Looking for a Supplier of Cancer Genetic Testing?
Fill out our quick contact form and we'll be in touch within 24 hours.
Get a free consultation